Shares of Inovio Pharmaceuticals Inc. INO slid 3.72% to $1.81 Tuesday, on what proved to be an all-around positive trading ...

Inovio Pharmaceuticals (NASDAQ:INO – Free Report) had its target price lowered by Royal Bank of Canada from $6.00 to $5.00 in a research report sent to investors on Wednesday,Benzinga reports. The ...

Shares of Inovio Pharmaceuticals Inc. INO shed 1.03% to $1.92 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index COMP rising 0.52% ...

Inovio plans to begin submitting the BLA for INO-3107 in mid-2025, with a goal of achieving FDA acceptance for filing by year-end 2025. Priority review will also be requested.

In a report released yesterday, Gregory Renza from RBC Capital maintained a Hold rating on Inovio Pharmaceuticals (INO – Research Report), with ...

Citizens JMP lowered the firm’s price target on Inovio (INO) to $12 from $18 and keeps an Outperform rating on the shares. Inovio expressed ...

Good afternoon, ladies and gentlemen, and welcome to the INOVIO Pharmaceuticals fourth quarter 2024 financial results ...

Operator: Good afternoon, and welcome to the Inovio Pharmaceuticals Fourth Quarter 2022 Financial Results Conference Call. Please note, this event is being recorded. Operator: Good day and welcome ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

However, I think aggressive growth investors might want to consider buying Madrigal Pharmaceuticals' shares. Some analysts project that Rezdiffra could generate peak annual sales of close to $3.5 ...

Shares of Inovio Pharmaceuticals stock opened at $1.98 on Wednesday. The company has a market capitalization of $51.68 million, a PE ratio of -0.94 and a beta of 0.89. Inovio Pharmaceuticals has a ...